Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient yields to meet the demands of new research initiatives and clinical applications is challenging using traditional approaches.
Download this article from Polyplus, now part of Sartorius, to learn how new technology enables AAV production with better yields, quality, and infectivity.